AstraZeneca: Crohn Disease trials
The registry lists 13 Crohn Disease studies with AstraZeneca as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 5Phase 2 6Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Open-label Extension Study of Brazikumab in Crohn's DiseaseTerminatedNCT03961815Phase 3Results posted
- An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's DiseaseTerminatedNCT03759288Phase 2/3Results posted
- Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's DiseaseTerminatedNCT02574637Phase 2Results posted
- Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.CompletedNCT01714726Phase 2Results posted
- Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in JapanCompletedNCT01514240Phase 3Results posted
- Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's DiseaseCompletedNCT00573469Phase 2Results posted
- Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyActive, not recruitingNCT06681324Phase 2
- Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseActive, not recruitingNCT06450197Phase 2
- Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.CompletedNCT06432764Phase 1
- Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's DiseaseCompletedNCT06053424Phase 1
- AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's DiseaseCompletedNCT05452304Phase 1
- Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White ParticipantsCompletedNCT05033431Phase 1
- Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease SubjectsCompletedNCT01258205Phase 1